



STATE OF IOWA

CHESTER J. CULVER, GOVERNOR
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
CHARLES J. KROGMEIER, DIRECTOR

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting December 2, 2009

**Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the minutes
2. Iowa Medicaid Enterprise Update(s)
3. Case Studies
4. Annual Smoking-Cessation Report to the Department – Final Draft
 - a) MMWR - State Medicaid Coverage for Tobacco-Dependence Treatments – United States, 2007 - Discussion
 - b) Varenicline Safety
5. Public Comment (See Conflict of Interest Disclosure Form)
6. Pro-DUR Edits
 - a) Armodafinil (*Nuvigil*) – Proposed Age Limit
 - b) Proposed Age Edit on Brand Ophthalmic Fluroquinolone Products
7. Prior Authorization
 - a) Smoking Cessation Therapy – Addition of Bupropion SR
 - b) Proton Pump Inhibitors (Age Limit on *Prevacid SoluTabs*)
 - c) Biologicals for Ankylosing Spondylitis
 - d) Short Acting Narcotics
 - e) Biologicals for Arthritis - New
 - f) Duloxetine (*Cymbalta*), Pregabalin (*Lyrica*), Milnacipran (*Savella*) - New
 - g) DPP-4 Inhibitors - New
 - h) Lidocaine Patch (*Lidoderm*) - New
 - i) Ergotamine Derivatives – Removal of Criteria
8. Public Comment (See Conflict of Interest Disclosure Form)

9. Focus Studies/Provider Education Initiatives
 - a) Drugs that cause Edema – Follow-up
 - b) Aripiprazole (*Abilify*) for Depression without Antidepressants – Initial Review
 - c) Chronic Use of Transdermal Scopolamine – Initial Review
 - d) Long Term Use of Short Acting Opioids – Initial Review
10. Miscellaneous
 - a) SMAC Update
 - b) MedWatch
11. Executive Closed Session
 - a) Approval of Minutes
 - b) Member Profiles
12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at info@iadur.org or (515) 725-1287